SLC1A5 and cancer: However, recent studies showed that ASCT2/SLC1A5-deficient mice exhibit normal growth and survival (Nakaya et al., 2014; Masle-Farquhar et al., 2017), indicating that targeting of ASCT2 for cancer therapy is likely to be well tolerated and elicit few adverse effects.